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valve and aortic root enlargement (6 years before). Two of 3 adults
had calcifications of the aortic valve, one of them with previous
aortic valve commissurotomy (23 years before).
In all patients the Ross operation was performed as an aortic
root replacement. Conventional cardiopulmonary bypass was used
with single venous cannulation and antegrade and retrograde blood
cardioplegia. The autotransplanted pulmonary valve was replaced
in all cases with a Contegra conduit having a tricuspid valve and a
22-mm internal diameter.
In the Ross operation (autotransplantation of the pulmonaryvalve in the aortic position), aortic or pulmonary homograftsare generally used as a pulmonary valve substitute.1 The pro-gressively reduced availability of homografts within the past
few years and the continuous research for an ideal valved conduit2
prompted us to search for alternative options. We therefore decid-
ed to perform a prospective study to evaluate the use of the
Contegra pulmonary valved conduit (Medtronic, Inc, Minneapolis,
Minn) as a pulmonary valve substitute during the Ross operation.
The Contegra conduit is a new biologic valved conduit consisting
of a zero-pressure glutaraldehyde-preserved heterologous bovine
jugular vein having a trileaflet venous valve (Figure 1). This bio-
logic valved conduit had already undergone experimental studies
in animals3 and preliminary clinical experience in complex con-
genital heart defects, with satisfactory results in our own practice.4
Materials and Methods
After having received approval from the institutional review board,
we enrolled all patients with indications for the Ross procedure in
a prospective study, starting in July 1999. In all cases informed
consent was obtained from the patients; in the 7 patients younger
than 18 years, the informed consent was obtained from the parents.
From July 1999 to November 2000, 10 patients with aortic
valve disease underwent a Ross operation with the pulmonary
valve being replaced with a Contegra pulmonary valved conduit.
Their mean age was 19.9 years (range 9-42 years), mean body
weight 56.9 ± 22.3 kg (range 26-91 kg), mean height 162.9 ± 15.0
cm (range 137-179 cm), and mean body surface area 1.6 ± 0.4 m2
(range 1.03-1.90 m2).
Among the 10 patients, 9 had aortic valve stenosis (in 8/9 with
a bicuspid valve) and 1 had aortic valve regurgitation. Two chil-
dren (9 and 10 years old) had moderate degrees of aortic regurgi-
tation after percutaneous balloon dilatation performed in the
neonatal period. One adolescent (15 years old) had a previous aor-
tic valvotomy performed in infancy. Another adolescent (13 years
old) had a previous aortic valve replacement with a prosthetic
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Figure 1. Photograph from above of the trileaflet venous valve in
the glutaraldehyde-preserved bovine jugular vein.
Figure 2. Late (16 months after Ross operation) postoperative
echocardiogram in a 10-year-old child showing the valve within
the right ventricular–pulmonary arterial conduit.
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Left and right ventricular outflow tracts were evaluated for the
presence and degree of aortic and pulmonary valve regurgitation
and for the presence and degree of any pressure gradient with intra-
operative transesophageal echocardiography and surface echocar-
diography 1 week after the operation and at any cardiologic fol-
low-up (Figure 2).
The right ventricular pressure gradient was compared with the
pressure gradient recorded in a group of 7 patients, mean age 30.4
years (range 16-46 years), who underwent a Ross operation in the
previous period with a conventional homograft (size 22-25 mm)
used to reconstruct the right ventricular outflow tract.
Results
At a mean follow-up of 8 months (range 1-17 months), all patients
are alive and asymptomatic, without cardiac medication or antico-
agulation, and free of reoperation. At the most recent echocardio-
graphic follow-up, pulmonary valve regurgitation was absent in 6
of 10 patients and trivial in the other 4 patients. The average peak
pressure gradient was 19.8 ± 9.9 mm Hg (range 6-38 mm Hg) with
an average mean pressure gradient of 11.0 ± 6.4 mm Hg (range 3-
24 mm Hg); in almost all cases, the pressure gradient was localized
at the level of the distal anastomosis of the conduit. It is important
to underline a mean pressure gradient of only 10 mm Hg, with a
peak gradient of 16 mm Hg recorded in the heaviest patient of our
series (91 kg body weight).
There was no statistical difference in the pressure gradient mea-
sured in our 7 patients after a Ross operation with conventional
homograft implantation on the right ventricular outflow tract,
where the mean peak pressure gradient was 22.7 ± 9.8 mm Hg and
the mean pressure gradient was 12.3 ± 6.5 mm Hg.
No progression of pulmonary valve regurgitation or of the pres-
sure gradient has been shown with echocardiography during the
follow-up in all patients.
Discussion
The second most common cause for reoperation after the Ross pro-
cedure is pulmonary homograft replacement, particularly in the
pediatric population, where a small homograft is inserted initially.5
This observation, together with the progressively reduced avail-
ability of homografts within the past few years, prompted us to
search for alternative options. The good results obtained with
Contegra conduits in the right ventricular outflow tract for recon-
struction of complex congenital heart defects suggested to us that
this conduit would be suitable as a pulmonary replacement during
the Ross operation.
The advantages observed in our initial clinical experience with
a total of 23 implants of this conduit are the following: (1) reliable
off-the-shelf availability; (2) proximal anastomosis without the
need for augmentation because of sufficient length available at
both the inflow and outflow; (3) easy tailoring and sewing; and (4)
adequate hemodynamic performance.
The preliminary results obtained with this conduit as a pul-
monary valve replacement during the Ross operation are encour-
aging: the new pulmonary valve remains free from regurgitation
(more than trivial) at a mean follow-up of 8 months.
The pressure gradient recorded at echocardiography, not differ-
ent than the gradient observed with conventional homografts, was
in almost all cases localized at the level of the distal anastomosis
of the conduit and therefore not due to the valved conduit itself,
confirming the adequacy of the hemodynamic performance of the
largest size available (22 mm internal diameter) for the largest
spectrum of the normal population. Of course, the pressure gradi-
ents recorded at rest should be evaluated during exercise, particu-
larly for larger patients or those who have a very active lifestyle.
Conclusions
The preliminary results of the recent introduction of the Contegra
valved conduit as a pulmonary valve substitute during the Ross
operation have been encouraging, with no early or late mortality,
no reoperations, and satisfactory hemodynamics.
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